[1] O’Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials. J Am Coll Cardiol 2012;60:106–111.
[2] Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2018;00:1–96.
[3]Qi X, Xu M, Yang H, Zhou L, et al. Comparing mortality and myocardial infarction between coronary artery bypass grafting and drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: a meta-analysis. Arch Med Sci. 2014;10(3):411–8.
[4] Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013;43(5):1006–13.
[5] Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009;373: 1190–7.
[6] Onuma Y, Wykrzykowska JJ, Garg S, et al. 5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials. JACC Cardiovasc Interv 2011;4:317–23).
[7] Brener SJ, Lytle BW, Casserly IP,et al. Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J 2006;27:413–418.
[8] Scarsini R, Zivelonghi C, Pesarini G, et al. Repeat revascularization: Percutaneous coronary intervention after coronary artery bypass graft surgery. Cardiovasc Revasc Med 2016;17(4):272–278.
[9] Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2007;99:1399–402.
[10] Mulukutla SR, Vlachos HA, Marroquin OC, et al. Impact of drug‐eluting stents among insulin-treated diabetic patients: A report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv 2008;1:139–147.
[11] Stenestrand U, James SK, Lindbäck J, et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: Long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J2010;31:177–186.
[12] Pendyala LK, Loh JP, Kitabata H, Minha S, et al. The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era. J Interv Cardiol. 2014;27(4):391–8.
[13]Yuichi Nakamura, Yasuhide Asaumi, Tadayoshi Miyagi, et al. Comparison of Long-Term Mortality in Patients with Previous Coronary Artery Bypass Grafting Undergoing Percutaneous Coronary Intervention with Versus Without Optimal Medical Therapy. Am J Cardiol 2018;122:206–212.
[14] Honda S, Asaumi Y, Yamane T, et al. Trends in the clinical and pathological characteristics of cardiac rupture in patients with acute myocardial infarction over 35 years. J Am Heart Assoc 2014;3:e000984.
[15] Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102:2180–2184.
[16] Marso SP, Mercado N, Maehara A, et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc Imaging 2012;5:S42–S52
[17] Schofield I, Malik R, Izzard A, et al. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002;106:3037–43.
[18] Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.
[19] Guandalini GS, Bangalore S. The Potential Effects of New Stent Platforms for Coronary Revascularization in Patients with Diabetes. Can J Cardiol 2018;34(5):653–664.
[20] Scarsini R, Zivelonghi C, Pesarini G, et al. Repeat revascularization: Percutaneous coronary intervention after coronary artery bypass graft surgery. Cardiovasc Revasc Med 2016;17(4):272–8.
[21] Baars T, Konorza T, Kahlert P, et al. Coronary aspirate TNF α reflects saphenous vein bypass graft restenosis risk in diabetic patients. Cardiovasc Diabetol 2013;12:12.
[22] Detre KM, Lombardero MS, Brooks MM, et al. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators. N Engl J Med 2000;342(14):989–97.
[23] The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation (BARI).Circulation 1997;96:1761–1769.
[24] Tailakh MA, Friger M, Zahger D, et al. Prospective study of the impact of diabetes mellitus newly diagnosed by glycated hemoglobin on outcomes in patients undergoing percutaneous coronary intervention. Eur J Intern Med 2017;37:69–74.
[25] De Luca G, Dirksen MT, Spaulding C, et al. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care 2013;36(4):1020–5..
[26] Wang H, Gao Z, Song Y, et al. Impact of Diabetes Mellitus on Percutaneous Coronary Intervention in Chinese Patients: A Large Single-Center Data. Angiology 2018;69(6):540–547.
[27] Pendyala LK, Loh JP, Kitabata H, et al. The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era. J Interv Cardiol 2014;27(4):391–8.
[28] Ahmed JM, Hong MK, Mehran R, et al. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol 2000; 36(4):1186–93
[29] Ashfaq S, Ghazzal Z, Douglas JS, et al. Impact of diabetes on five-year outcomes after vein graft interventions performed prior to the drug-eluting stent era. J Invasive Cardiol 2006;18(3):100–5.
[30] Coolong A, Baim DS, Kuntz RE, et al. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 2008;117:790–797.
[31] Brilakis E S, O’Donnell C I, Penny W, et al. Percutaneous Coronary Intervention in Native Coronary Arteries Versus Bypass Grafts in Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. JACC Cardiovasc Interv 2016, 9(9):884–893.